The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.

The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Am Heart J. 2005 Jun; 149(6):994-1002.

View in: PubMed

subject areas

Acute Disease
Angina, Unstable
Double-Blind Method
Electrocardiography
Humans
Middle Aged
Multicenter Studies as Topic
Myocardial Infarction
Peptides
Platelet Glycoprotein GPIIb-IIIa Complex
Prospective Studies
Randomized Controlled Trials as Topic
Research Design
Syndrome
Time Factors

authors with profiles

Robert Harrington